Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months

Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months

identical-appearing placebo tablets by mouth, two times per day for 6 months

Colorectal Adenomas

patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months

100mg Berberine hydrochloride

patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months

300mg Berberine hydrochloride

patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months

Placebo Oral Tablet

Xijing Hospital of Digestive Disease

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

The Effect of Berberine Hydrochloride in Familial Adenomatous Polyposis:a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial

The primary objective of this study is to investigate the number and diameters of colorectal polyps after Berberine hydrochloride or placebo intervention. To ascertain that the same area was scored at base line and at month 6, polyps were counted in pairs of photographs. One investigator, other than the endoscopist, who did not know the treatment, performed the scoring. Videotapes were used to resolve ambiguities and confirm polyp counts. The diameter of those colorectal adenomas was measured in millimeters with a graduated scale passed through the colonoscopy biopsy channel.

xiaohua li

Director of colorectal surgery center

Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years

identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years

patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.

Berberine hydrochloride

pill manufactured to mmic Berberine hydrochloride 100mg tablet

Placebo

A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

A Randomized Trial of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

The proportion of patients in whom one or more colorectal adenomas were investigated during the period from one year after randomization through the anticipated surveillance follow-up examination. The development of colorectal adenomas was assessed with an Olympus flexible video colonoscopy. One endoscopic investigator, who did not review the records of previous examinations, made all the assessments.

The numbers or diameters of those new colorectal adenomas were analyzed during the period from one year after randomization through the anticipated surveillance follow-up examination. The endoscopic investigator, who did not review the records of previous examinations, counted the total number of colorectal adenomas, and the examination was recorded on videotape. The diameter of those colorectal adenomas was measured in millimeters with a graduated scale passed through the colonoscopy biopsy channel.

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.

Metastatic Cancer

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

Non Chemotherapy

Chemotherapy and target therapy

Chinese herb medicine

Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of medicine

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Clinical Studies by Using Alphacait to Screen Drug Combinations for Advanced Solid Tumor

Progression-free survival (PFS) is defined as the time from assignment in the trial to disease progression or death from any cause.

Defined as the time from assignment to death from any cause.

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response or stable disease to therapy

Drug-related adverse reactions must be recorded, mainly in the following：myelosuppression including neutropenia, anemia and thrombocytopenia;Cardiac toxicity; muscle fatigue, pain, imbalance; Oral ulcers: the patient's gums, cheeks, throat and tongue are prone to ulcers;nausea, vomiting, constipation or diarrhea;hair loss;skin discomfort;hormonal fluctuations, sexual dysfunction, infertility; damage of the kidney;anxiety and depression.

Expectations of exploratory markers for this study include the status of exploratory biomarkers associated with immunohistochemistry (IHC) or quantitative reverse transcription polymerase chain reaction (qRT-PCR), a new generation sequencing method (NGS), Nanostring technique and / or other methods to evaluate archived and/or newly acquired tumor tissue, as well as its association with disease status and/or (Including but not limited to somatic mutations and other exploratory markers) according to qRT-PCR and NGS techniques, and to evaluate the relationship between the therapeutic response, the status of the biomarker during exploratory treatment and during treatment, and the evaluation of plasma, serum or whole blood samples (including but not limited to somatic mutations and other exploratory markers) The association of the above markers with disease status and / or therapeutic response.

Through publication after study completion

Haining Health-Coming Biotech Co., Ltd.

Alphacait, LLC

This single center, open-label, single arm, non-randomized study is designed to evaluate safety, progression-free survival(PFS),overall survival (OS), objective response rate (OPR), and disease control rate (DCR) of chemotherapy or target therapy or chinese medicine based on the Alphacait screening system in subjects with advanced malignant tumor.

supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years

identical-appearing placebo supplements for 2-3 years

Colorectal Adenoma

supplement of placebo two times per day for 2-3 years

placebo

Department of Gastroenterology, the Seventh Medical Center of PLA General Hospital

Department of Gastroenterology, Zhongshan Hospital, Xiamen University

Department of Gastroenterology, Nanfang Hospital, Southern Medical Univerisity

Division of Gastroenterology and Hepatology, The Affiliated DrumTower of Nanjing University Medical School

Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology & Hepatology, Ministry of Health

Department of Gastroenterology, the Shanghai Tenth People's Hospital, Tongji University

Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University

Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence

A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas

The primary objective of this study is to investigate recurrence rates of colorectal adenoma (CRA) after Berberine hydrochloride or placebo intervention.

The incidence of all polypoid lesions or advanced colorectal adenoma or colorectal cancer after Berberine hydrochloride or placebo intervention

berberine hydrochloride/cáncer

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence

La base de datos de hierbas medicinales más completa respaldada por la ciencia